The UK will launch a new regulatory Innovative Devices Access Pathway (IDAP) later in 2023.
What is the current status of the pathway?
Plans are advancing for a new regulatory pathway that facilitates the development of innovative technologies, by providing innovators and manufacturers with a multi-partner support service including targeted scientific advice that brings new products to patients sooner.
Who will operate the new pathway?
The Innovative Devices Access Pathway (IDAP) will be operated by the following:
- Medicines and Healthcare products Regulatory Agency (MHRA)
- the National Institute for Health and Care Excellence (NICE)
- Health Technology Wales (HTW)
- Scottish Health Technology Group (SHTG)
What is the ambition for this new pathway?
The ambition of this new programme is to bring innovative technologies and solutions to the forefront of the National Health Service (NHS), through a new, integrated support service for developers that will include enhanced opportunities for engagement.
The aim is to help take uncertainty out of the route to access, bringing innovative technologies to patients that can transform health outcomes.
Planned 2023 pilot launch
From today, innovators of medical technology (commercial or non-commercial, UK based or international) that addresses clinical needs are being encouraged to register for further information ahead of a planned 2023 pilot launch. Please send an email with details to IDAPEnquiries@mhra.gov.uk.
How will the IDAP partners use the lessons learnt from the pilot?
Once up-and-running, the IDAP partners will use the lessons learned from the pilot to help develop the future IDAP pathway, creating an end-to-end visible framework that supports innovators generate the evidence they need to achieve regulatory approval, heath technology assessment decisions, and patient access in the NHS.
What is IDAP expected to demonstrate?
According to Dr Marc Bailey, MHRA Chief Science and Innovation Officer:
“The new IDAP will demonstrate how the UK regulator, health technology assessment and the healthcare system are working together to deliver safe, effective, and earlier innovative medical products to patients, establishing the UK as a centre for medical innovation”
Source: MHRA